Comparative Pharmacology
Head-to-head clinical analysis: JUNEL 1 20 versus MICROGESTIN 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JUNEL 1 20 versus MICROGESTIN 1 20.
JUNEL 1/20 vs MICROGESTIN 1/20
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Ethinyl estradiol is a synthetic estrogen that suppresses gonadotropin release by inhibiting hypothalamic GnRH secretion. Norethindrone acetate is a progestin that suppresses LH surge and thickens cervical mucus to inhibit sperm penetration and alters endometrial development.
Combination oral contraceptive containing estrogen (ethinyl estradiol) and progestin (norethindrone acetate). Inhibits gonadotropin secretion (FSH, LH) via negative feedback, preventing ovulation. Also causes cervical mucus thickening and endometrial thinning.
One tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days, then repeat.
One tablet (norethindrone acetate 1 mg / ethinyl estradiol 20 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
None Documented
None Documented
Ethinyl estradiol: 12-24 hours (terminal half-life). Norethindrone: 5-14 hours (terminal half-life). Achieves steady state within 5-7 days.
Norethindrone: 5.2-12.8 hours (mean ~8 hours); Ethinyl estradiol: 7-20 hours (mean ~13 hours); hepatic impairment prolongs.
Renal: 30-50% (metabolites as glucuronide and sulfate conjugates). Fecal: 20-40% (biliary elimination of metabolites). Unchanged drug: <5% renal.
Renal: 40% as metabolites, 20% as glucuronide and sulfate conjugates; Fecal: 35%; Biliary: <5%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive